ESPEROCT® is a long-acting recombinant product for the treatment of hemophilia A.
NHF maintains its prestigious 4-star rating from Charity Navigator, the largest independent charity evaluator in the US.
The organizations continue to monitor the outbreak.
The new guidance issued by the FDA seeks to support both innovation and patient safety.
The Hemophilia SNF Access Act will rectify a long-standing problem for Medicare beneficiaries with hemophilia and other bleeding disorders.
The summit was convened to address recent issues regarding recalls and product safety.
The Green Park Collaborative and the National Hemophilia Foundation launch project to develop a PROM to measure mental health outlook.
This study was based on a systematic literature review of peer-reviewed articles relevant to VWD and pregnancy, published between January 1982 and May 2019.
Nationally recognized researcher Dr. Leonard Valentino to lead the Foundation into the future.
Groups argue patients need a quick resolution to ensure access to care.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car